The U.S. Food and Drug Administration has issued updated guidance clarifying the conditions under which compounding pharmacies may prepare GLP-1 receptor agonists and related peptide products. The guidance follows a period in which several of these drugs were listed as in shortage, a status that had temporarily expanded the role of compounders in meeting demand.
Under the updated framework, compounding is more tightly limited once a commercial product is no longer designated as being in shortage. The agency states that the changes are intended to reinforce existing rules rather than create new ones, and to reduce the volume of products made outside the standard manufacturing and approval pathway.
For people who have relied on compounded versions of these medications, the practical effect may be reduced availability from some pharmacies. Patients and prescribers are likely to see more variation in what individual compounders can offer, depending on each product’s shortage status at a given time.
The guidance addresses GLP-1 medications most directly, but it also touches the broader category of peptide-based products prepared by compounders. Tesamorelin, a growth-hormone-releasing-hormone analog approved for a specific indication, sits in this wider regulatory conversation, though it is governed by its own approval status rather than the GLP-1 shortage lists.
It is worth noting that guidance documents describe the FDA’s current thinking and are not themselves binding law. How the guidance is applied in practice will depend on enforcement decisions and on whether particular products return to or leave shortage status.
Source note: This summary is based on the FDA’s published compounding guidance and accompanying agency statements. Readers should consult the original documents and a qualified clinician for decisions about their own care.